New medicines that spur weight loss and address diabetes have been getting the public—and also the pharmaceutical marketplace—by storm. The latest entrant, Zepbound, not long ago joined Ozempic, Wegovy, Victoza and Other folks inside of a escalating class of prescription drugs called GLP-1 receptor agonists.have severe challenges with your stom